Research programme: peptide therapeutics - Kallyope/Novo Nordisk
Latest Information Update: 12 Sep 2024
At a glance
- Originator Kallyope
- Developer Kallyope; Novo Nordisk
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Peptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
- Research Diabetes mellitus